UroGen Pharma Ltd. (URGN)

41.34 +0.11 (+0.27%) USD  |  NASDAQ  |  Sep 25, 16:00
41.34 0.00 (0.00%) After-Hours: 19:59
More

UroGen Pharma Research and Development Expense (Annual) : 67.11M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for URGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 2015. Start Trial.
Date Value
December 31, 2025 67.11M
December 31, 2024 57.14M
December 31, 2023 45.61M
December 31, 2022 52.91M
December 31, 2021 47.64M
December 31, 2020 45.27M
Date Value
December 31, 2019 49.30M
December 31, 2018 36.93M
December 31, 2017 18.70M
December 31, 2016 10.29M
December 31, 2015 10.52M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Xencor, Inc. 239.43M
MeiraGTx Holdings Plc 129.32M
Insmed, Inc. 771.09M
Ironwood Pharmaceuticals, Inc. 93.26M
Viking Therapeutics, Inc. 344.96M